Fosamax Femur Fractures: 2012 Update From FDA And Medical Journals Re: Health & Safety And Litigation
Using Fosamax For More Than Three (3) To Five (5) Years Significantly Increases The Risk Of Atypical / Low-Stress Thigh Bone Breaks
In May 2012 there were medical journal articles in The New England Journal of Medicine (NEJM) and the Archives of Internal Medicine which are important as regards public health and safety but, also, relevant to the Fosamax - femur fracture litigation.
First, the NEJM articles presented the findings of an FDA review of Fosamax as well as other bisphosphonate drugs prescribed for osteoporosis and, sometimes, osteopenia (moderate to low bone density that is not low enough to be called osteoporosis). The FDA analysis called into question the fracture-prevention benefits of long-term Fosamax use. Specifically, for perhaps 60% to 70% of women currently using Fosamax and other bisphosphonates there is little to no benefit when these osteoporosis medications are used for more than three (3) to five (5) years.
Next, we turn to the Archives of Internal Medicine articles concerning a Swiss study which found that the use of Fosamax and other bisphosphonates appears to be associated with an increased risk of low-stress, or atypical, fractures of the femur (thigh bone), and that the degree of fracture risk may be determined by the duration of Fosamax treatment. The bottom line: There is an increased risk of atypical fractures (low-stress) of the femur in women who have used Fosamax for more than five (5) years.
For more about the FDA Fosamax analysis and the Swiss bisphosphontes study, see "Risk Of Femur Fractures From Osteoporosis Drugs Fosamax, Boniva, Actonel, And Reclast Related To Number Of Years Used".
According to the drug company's Annual Report, as of December 2011 there were 1,165 Fosamax - femur fracture lawsuits filed against Merck.
Go to Free Fosamax Case Evaluation form >>
Read more on our Fosamax Information Page >>